Answers are grounded in this paper and cite their sources.
Background/Objectives: Long-term evidence on microbiome-targeted nutraceuticals in inflammatory bowel disease (IBD) is limited. This exploratory pilot study (feasibility and parameter estimation) described clinical, microbiome, and fecal metabolomic changes during 12 months of supplementation with two regimens. Methods: Single-center, double-blind, nonrandomized, two-arm pilot trial without a placebo arm. Patients with ulcerative colitis (UC) or Crohn’s disease (CD) on stable standard-of-care therapy, all previously using prebiotics, received fructooligosaccharides, galactooligosaccharides, yeast β-glucan, and minerals, alone (Suppl) or with silymarin (Suppl Plus), and were assessed at baseline, 6, and 12 months. The main clinical endpoint, analyzed as exploratory, was remission or mild activity at 12 months (UC, Mayo endoscopic subscore <2; CD, Simple Endoscopic Score for Crohn’s Disease <8); secondary endpoints included fecal calprotectin, C-reactive protein, 16S rRNA gene profiles, and fecal nuclear magnetic resonance metabolomics. Registration (retrospective): Brazilian Registry of Clinical Trials, RBR-7hvd26h. Results: Of 87 participants enrolled, 75 completed follow-up (UC, n=50; CD, n=25); four died. In UC, the proportion in remission or mild activity was 44.0% at baseline and 82.0% at 12 months (p<0.001), and median calprotectin was 406 and 286 µg/g (p=0.046). In CD, the proportion was 88.0% at both time points (p=1.000), without calprotectin change (p=0.968). No difference between arms was detected (UC, p=1.000; CD, p=0.593), with wide confidence intervals. Flatulence increased (2.7% to 16.0%; p=0.009). Genus-level α-diversity increased, and Dorea and Blautia were enriched in UC at 6 months in both differential abundance tools. Fecal xanthine, 4-pyridoxate, and nicotinate signals increased in both diseases (nominal p values). Conclusions: In this nonrandomized pilot without a placebo arm, the changes observed in UC cannot be attributed to supplementation, and the comparison between formulations was underpowered. The findings are hypothesis-generating; a randomized, placebo-controlled trial is ongoing (recruitment completed; RBR-7hvd26h).
No takes yet. Share an insight, caveat, or question.
Coelho et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: